⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEM News
Tempus AI, Inc. Class A Common Stock
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
prnewswire.com
TEM
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
businesswire.com
TEM
Tempus Announces New Study in JCO Precision Oncology Validating PurIST ® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
businesswire.com
TEM